Form 4: Cero Therapeutics Holdings Director, Michael Byrnes, Acquires Stock Options
SEC Form 4
Director Michael Byrnes acquired stock options in Cero Therapeutics Holdings, Inc. on March 25, 2024.
Summary
- On March 25, 2024, Michael Byrnes, a director of Cero Therapeutics Holdings, Inc., acquired 112,500 stock options with an exercise price of $1.77.
- The options vest in 36 monthly installments from the grant date, contingent upon continued service.
- Following the transaction, Byrnes directly owns 112,500 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing detailing an insider transaction. The acquisition of options could be seen as a slightly positive signal, but it's not definitive.
Positives
- The acquisition of stock options by a director signals confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions in their company's securities. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of the stock option transaction. |
| 03/24/2034 | Expiration date of the stock options. |
| 03/27/2024 | Date of signature for the Form 4 filing. |
Keywords
stock options, Form 4, derivative securities, Cero Therapeutics Holdings, insider trading, Michael Byrnes, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.